Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Raffi

Showing results (161-170 of 224) with videos related to

Pageof 23
Sort By:
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|December 7, 2017
An outbreak of airborne tularaemia in France, August 2004V Siret, D Barataud, M Prat, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 10, 2006
An outbreak of airborne tularaemia in France, August 2004V Siret, D Barataud, M Prat, et al.
HIV Medicine|April 28, 2007
Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugsV Le Moing, R Thiébaut, G Chêne, et al.
Annales De Medecine Interne|January 1, 1996
[Risk factors of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention]C Leport, P Ambroise-Thomas, C Bazin, et al.
The Journal of Infectious Diseases|July 29, 2000
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patientsJ M Molina, F Ferchal, C Rancinan, et al.
Diabetes & Metabolism|March 14, 2019
Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patientsJ-P Bastard, C Couffignal, S Fellahi, et al.
Alimentary Pharmacology & Therapeutics|June 15, 2018
Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohortA Provoost, M Dramé, L Cotte, et al.
Presse Medicale (Paris, France : 1983)|March 30, 1996
[Risk factors of the occurrence of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention. Proposals of the Toxoplasmosis and other protozoan infections Group. Coordinated action N.5 - 1996 February]C Leport, P Ambroise-Thomas, C Bazin, et al.
HIV Medicine|August 24, 2006
Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO studyV Reliquet, C Allavena, C François-Brunet, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupM Savès, F Raffi, P Clevenbergh, et al.
Pageof 23

Showing results (161-170 of 224) with videos related to

Sort By:
Pageof 23
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|December 7, 2017
An outbreak of airborne tularaemia in France, August 2004V Siret, D Barataud, M Prat, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 10, 2006
An outbreak of airborne tularaemia in France, August 2004V Siret, D Barataud, M Prat, et al.
HIV Medicine|April 28, 2007
Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugsV Le Moing, R Thiébaut, G Chêne, et al.
Annales De Medecine Interne|January 1, 1996
[Risk factors of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention]C Leport, P Ambroise-Thomas, C Bazin, et al.
The Journal of Infectious Diseases|July 29, 2000
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patientsJ M Molina, F Ferchal, C Rancinan, et al.
Diabetes & Metabolism|March 14, 2019
Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patientsJ-P Bastard, C Couffignal, S Fellahi, et al.
Alimentary Pharmacology & Therapeutics|June 15, 2018
Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohortA Provoost, M Dramé, L Cotte, et al.
Presse Medicale (Paris, France : 1983)|March 30, 1996
[Risk factors of the occurrence of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention. Proposals of the Toxoplasmosis and other protozoan infections Group. Coordinated action N.5 - 1996 February]C Leport, P Ambroise-Thomas, C Bazin, et al.
HIV Medicine|August 24, 2006
Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO studyV Reliquet, C Allavena, C François-Brunet, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2000
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupM Savès, F Raffi, P Clevenbergh, et al.
Pageof 23